Belupo has recently delivered the first consignment of its product Lorsilan (lorazepam)

Belupo has recently delivered the first consignment of its product Lorsilan (lorazepam) to the UK market, in the quantity of more than 200.000 packs of 1mg and 2,5 mg dosage forms. This product has been developed in Belupo and is administered in short term symptomatic treatment of anxiety, tension, agitation and insomnia. The product has been a part of Belupo's portfolio for the past twenty years and last year it has brought over 7 MIO kn of sales on the Croatian pharmaceutical market.

Precondition for the export of generic equivalent of Lorsilan to the British market was the completed registration procedure and its approval by the demanding British regulatory authority (MHRA). Partner for distribution of Belupo's Lorazepam to the UK Market is Zista Pharma, a subsidiary of Eywa Pharma PTE LTD, Singapore, a global pharmaceutical company

The UK market is the 20th international market to which Belupo exports its products. The rest of the international markets bring in 56,8% of sales to Belupo, the biggest markets being the Russian Federation and Bosnia and Herzegovina. In line with its business strategy for the next 4 years, along with opening new markets Belupo intends also to extend its portfolio within the focus therapeutical areas on the current markets.